<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151761</url>
  </required_header>
  <id_info>
    <org_study_id>HEP0032</org_study_id>
    <secondary_id>HEP0032</secondary_id>
    <nct_id>NCT01151761</nct_id>
  </id_info>
  <brief_title>Phase II SBRT &amp; Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation</brief_title>
  <official_title>Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine progression-free survival at 12 months for
      stereotactic body radiotherapy (SBRT) and chemotherapy for unresectable hilar
      cholangiocarcinoma (CCA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators hope to learn more about neoadjuvant SBRT and chemotherapy for unresectable
      CCA, and if SBRT followed by chemotherapy can lead to successful liver transplantation. This
      knowledge is important for this patient group as this disease is a highly lethal malignancy
      that often presents as unresectable, however surgery or transplantation are the only curative
      options.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Progression free survival is defined to be the time to progression of disease or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Pathologic complete response will be defined as no residual tumor cells seen on the explanted liver specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CA 19-9 Levels</measure>
    <time_frame>12 months</time_frame>
    <description>Initial level of Cancer antigen 19-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>the estimated probability for the percentage of participants with overall survival at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Transplant Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of patients receiving liver transplant among patients who initially have tumors â‰¤3 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Local Progression at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of patients who experienced a local recurrence at 12 months with death as a competing risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Transplant Conversion Rate</measure>
    <time_frame>12 months</time_frame>
    <description>The ability to successfully perform liver transplant among patients who initially have tumor &gt;3 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Overall Survival</measure>
    <time_frame>18 months</time_frame>
    <description>The time to overall survival is defined as the time to death from any cause. The median was determined via Kaplan Meier methodology.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Hepatobiliary Neoplasm</condition>
  <condition>Liver Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <condition>Cancer of Gallbladder</condition>
  <arm_group>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>External photon radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>100 mg/m2, IV</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25 mg/m2, IV</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Platinol-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 2, based on Calvert formula, IV</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m2, PO</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5FU</intervention_name>
    <description>200 mg/m2</description>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
    <other_name>Fluorouracil</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Carac</other_name>
    <other_name>Efudix</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver transplantation</intervention_name>
    <arm_group_label>SBRT, Chemo and Liver Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cholangiocarcinoma by any of the below:

               -  Positive transcatheter biopsy or brush cytology

               -  CA 19-9 &amp;#8805; 100mg/mL with a malignant-appearing stricture on cholangiography

               -  Biliary ploidy by fluorescent in situ hybridization with a malignant stricture on
                  cholangiography

          -  Liver tumors not to exceed 8 cm in greatest axial dimension (800 cc of uninvolved
             liver)

          -  Unresectable tumor above cystic duct

          -  Hepatic lesion in patients for whom surgical resection is not possible or would not
             result in an opportunity for cure by any of the below:

               -  Bilateral segmental ductal extension

               -  Encasement of the main portal vein

               -  Unilateral segmental ductal extension with contralateral vascular encasement

               -  Unilateral atrophy with either contralateral segmental ductal or vascular
                  (hepatic artery, portal vein) involvement

          -  Ascites is allowed if the Model for End-Stage Liver Disease (MELD) score is &lt;15[1]

          -  Age &gt; 18 years old

          -  Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix 1)

          -  Lab values within 2 wks prior to randomization:

               -  See STUDY SCHEMA for specific blood count inclusion criteria: ANC &amp;#8805; 500 x
                  109/L (&amp;#8805; 1500/mm3), Platelets &amp;#8805; 5 x 109/L (&amp;#8805; 50,000/mm3), Hgb
                  &amp;#8805; 9g/dL

               -  Adequate liver function: Total bilirubin &amp;#8804;1.5 x upper limit of normal
                  (ULN); ALT and/or AST &amp; alkaline phosphatase &amp;#8804; 5 x ULN.

               -  Adequate biliary drainage, with no evidence of active uncontrolled infection
                  (patients on antibiotics are eligible).

               -  See STUDY SCHEMA for specific renal function inclusion criteria: Adequate renal
                  function with a calculated GFR &amp;#8805; 40 ml/min. If the calculated GFR is below
                  40 ml/min a 24 hour urine creatinine clearance can be used.

               -  Albumin &gt; 2.5 mg/dL

               -  INR &amp;#8804; 1.5

          -  Life expectancy &gt; 6 months

          -  Capable of giving written informed consent

        Exclusion Criteria:

          -  Prior radiotherapy to the upper abdomen

          -  Contraindication to receiving radiotherapy

          -  Prior chemotherapy

          -  Prior biliary resection or attempted resection

          -  Prior transperitoneal biopsy

          -  Large esophageal varices without band ligation

          -  Active GI bleed or within 2 weeks of study enrollment

          -  Ascites refractory to medical therapy or shunting

          -  Active/unresolved biliary tract obstruction

          -  Presence of multifocal, lymphatic, or extrahepatic metastases

          -  Participation in another concurrent treatment protocol

          -  If history of other primary cancer, subject eligible only if she or he has:

               -  Curatively resected non-melanomatous skin cancer

               -  Curatively treated cervical carcinoma in situ

               -  Other primary solid tumor curatively treated with no known active disease present
                  and no treatment administered for the last 3 years

          -  Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in
             the view of the investigator makes it undesirable for the patient to participate in
             the trial

          -  Any psychiatric or other disorder (eg brain metastases) likely to impact on informed
             consent

          -  Pregnancy or breast-feeding

          -  While not excluded, patients with significant impaired hearing must be made aware of
             potential ototoxicity and may choose not to be included. If included, baseline
             audiograms are recommended and, in those given cisplatin, should be followed by repeat
             audiograms prior to cycle 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>April 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2016</results_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel T. Chang</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The location is the Stanford Cancer Center. The study was open to accrual 1/18/2011. The study closed on 9/28/2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SBRT, Chemotherapy and Liver Transplantation</title>
          <description>The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SBRT, Chemotherapy and Liver Transplantation</title>
          <description>The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival at 12 Months</title>
        <description>Progression free survival is defined to be the time to progression of disease or death.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival at 12 Months</title>
          <description>Progression free survival is defined to be the time to progression of disease or death.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The median Progression Free Survival (PFS) time as calculated using Kaplan Meier methodology. For PFS both death and progression are counted as events.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>months</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
            <estimate_desc>There were only two patients in the study. Both died without having any local failure. One patient died at 10 months, the other at 7 months. The range for the 95%CI is both the full range and the 95%CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>Pathologic complete response will be defined as no residual tumor cells seen on the explanted liver specimen.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate</title>
          <description>Pathologic complete response will be defined as no residual tumor cells seen on the explanted liver specimen.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CA 19-9 Levels</title>
        <description>Initial level of Cancer antigen 19-9</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CA 19-9 Levels</title>
          <description>Initial level of Cancer antigen 19-9</description>
          <units>U/ml</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3329.1" lower_limit="62.2" upper_limit="6596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 12 Months</title>
        <description>the estimated probability for the percentage of participants with overall survival at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>There were only two patients analyzed. Please take that under advisement when looking at the results.</population>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 12 Months</title>
          <description>the estimated probability for the percentage of participants with overall survival at 12 months.</description>
          <population>There were only two patients analyzed. Please take that under advisement when looking at the results.</population>
          <units>probability</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Transplant Rate</title>
        <description>The number of patients receiving liver transplant among patients who initially have tumors â‰¤3 cm</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Transplant Rate</title>
          <description>The number of patients receiving liver transplant among patients who initially have tumors â‰¤3 cm</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Local Progression at 12 Months</title>
        <description>the proportion of patients who experienced a local recurrence at 12 months with death as a competing risk</description>
        <time_frame>12 months</time_frame>
        <population>Neither of the two patients that participated in the study had a local recurrence prior to dying.</population>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Local Progression at 12 Months</title>
          <description>the proportion of patients who experienced a local recurrence at 12 months with death as a competing risk</description>
          <population>Neither of the two patients that participated in the study had a local recurrence prior to dying.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>proportion of participants</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>None of the two patients who participated had a local recurrence before they died.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Transplant Conversion Rate</title>
        <description>The ability to successfully perform liver transplant among patients who initially have tumor &gt;3 cm</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Transplant Conversion Rate</title>
          <description>The ability to successfully perform liver transplant among patients who initially have tumor &gt;3 cm</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Overall Survival</title>
        <description>The time to overall survival is defined as the time to death from any cause. The median was determined via Kaplan Meier methodology.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SBRT and Chemo</title>
            <description>The patients in this arm receive SBRT and chemo in the hope of surviving long enough to have a liver transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Overall Survival</title>
          <description>The time to overall survival is defined as the time to death from any cause. The median was determined via Kaplan Meier methodology.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The entire period of the study, 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SBRT, Chemotherapy and Liver Transplantation</title>
          <description>The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure (encephalopathy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Chang</name_or_title>
      <organization>Stanford University Cancer Center</organization>
      <phone>650-724-3547</phone>
      <email>dtchang@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

